TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31816049

Group type: EXPERIMENTAL
Intervention: Smoking cessation medication
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Quit attempts
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Quit motivation
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Use of smoking cessation medications
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Use of smoking cessation counseling
Number of subjects: 482
Study: 31138068

Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 28524457

Group type: EXPERIMENTAL
Intervention: Motor cortex stimulation (MCS) at 100%, 83.3%, 66.7%, or 50% of the time in 30-min intervals
Number of subjects: 6
Study: 25524432

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 4447

Group type: COMPARATOR
Intervention: Metformin/Sulfonylurea (Control)
Number of subjects: 4447

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (Women)
Number of subjects: 4447

Group type: COMPARATOR
Intervention: Metformin/Sulfonylurea (Control, Women)
Number of subjects: 4447

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (Men)
Number of subjects: 4447

Group type: COMPARATOR
Intervention: Metformin/Sulfonylurea (Control, Men)
Number of subjects: 4447
Study: 23499569

Group type: EXPERIMENTAL
Intervention: Rely-X Veneer resin-coating with a seating load of 5N
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Rely-X Veneer resin-coating with a seating load of 30N
Number of subjects: 288

Group type: COMPARATOR
Intervention: Uncoated controls
Number of subjects: 288
Study: 21130194

Group type: EXPERIMENTAL
Intervention: Pandemic H1N1 vaccine first, followed by seasonal vaccine 21 days later
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Seasonal vaccine first, followed by pandemic H1N1 vaccine 21 days later
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Both vaccines administered simultaneously
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 151
Study: 19943971

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Vigorous intensity supervised exercise program
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Metformin and vigorous intensity exercise
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Adherence to the REACH program
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: COMPARATOR
Intervention: Moderate intensity supervised exercise program
Number of subjects: 72
Study: 17296639

Group type: EXPERIMENTAL
Intervention: Long-term targeted therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (age-matched subjects)
Number of subjects: 70
Study: 15219636

Group type: EXPERIMENTAL
Intervention: Cortisol ApEn in depressed men
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ACTH ApEn in depressed men
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cortisol and ACTH levels derived from cosinor analysis
Number of subjects: 30
Study: 16113556

Group type: EXPERIMENTAL
Intervention: Betamethasone (two doses, 24 hours apart)
Number of subjects: 0
Study: 10493479

Group type: EXPERIMENTAL
Intervention: Prophylactic retrocolic gastrojejunostomy
Number of subjects: 87

Group type: COMPARATOR
Intervention: No gastrojejunostomy
Number of subjects: 87
Study: 8709687

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/kg daily, intramuscularly, for three doses)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 1770216

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 2 gm/day for 30 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC)
Number of subjects: 10
Study: 6800629

Group type: EXPERIMENTAL
Intervention: Jejunal feeding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enteral nutrition (oral feeding)
Number of subjects: 0
Study: 31086050

Group type: EXPERIMENTAL
Intervention: Online Hemodiafiltration (HDF)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Low-flux Hemodialysis (HD)
Number of subjects: 404
Study: 28374218

Group type: EXPERIMENTAL
Intervention: BEST MOOD intervention
Number of subjects: 64

Group type: COMPARATOR
Intervention: PAST (treatment-as-usual)
Number of subjects: 64
Study: 26745346

Group type: EXPERIMENTAL
Intervention: Training interventions for social skills development
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polish treatment group
Number of subjects: 0

Group type: COMPARATOR
Intervention: German control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Younger German pupils (indirect effectiveness of interventions)
Number of subjects: 0
Study: 25227543

Group type: EXPERIMENTAL
Intervention: mCIMT plus trunk restraint
Number of subjects: 22

Group type: COMPARATOR
Intervention: mCIMT
Number of subjects: 22
Study: 22782571

Group type: EXPERIMENTAL
Intervention: Berocca™
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: CNE™ low dose (CNE4)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: CNE™ high dose (CNE8)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (nonrandomized, n=25)
Number of subjects: 91
Study: 19897418

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus cetuximab (400 mg/m2 initial dose, followed by seven weekly doses at 250 mg/m2)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Cetuximab-treated patients with acneiform rash of at least grade 2 severity
Number of subjects: 424
Study: 18445258

Group type: EXPERIMENTAL
Intervention: Peer-mediated interventions (STI/HIV education, condoms, facilitated HIV testing, treatment and care services)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Peer-mediated interventions
Number of subjects: 503
Study: 16178492

Group type: EXPERIMENTAL
Intervention: BoNTA 225 U
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: BoNTA 150 U
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: BoNTA 75 U
Number of subjects: 702

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 702
Study: 11840116

Group type: COMPARATOR
Intervention: Walking velocity of 3.8 km/h and higher
Number of subjects: 39

Group type: COMPARATOR
Intervention: Walking velocity from 1.4 to 3.0 km/h
Number of subjects: 39

Group type: COMPARATOR
Intervention: Overall gait characteristics
Number of subjects: 39

Group type: COMPARATOR
Intervention: Coordination measures
Number of subjects: 39
Study: 10520778

Group type: EXPERIMENTAL
Intervention: Thrombolytic administration
Number of subjects: 1817

Group type: COMPARATOR
Intervention: Culprit artery with TIMI grade 3 flow
Number of subjects: 1817

Group type: EXPERIMENTAL
Intervention: Adjunctive percutaneous transluminal coronary angioplasty (PTCA) of the culprit artery
Number of subjects: 1817

Group type: COMPARATOR
Intervention: Culprit artery PTCA with abnormal nonculprit artery flow (CTFC >= 28 frames)
Number of subjects: 1817

Group type: COMPARATOR
Intervention: Global CTFC
Number of subjects: 1817
Study: 7720766

Group type: EXPERIMENTAL
Intervention: FCH-free GTN spray with low ethanol content (TL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FCH-containing GTN spray (R)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FCH-free GTN spray with higher ethanol content (TH)
Number of subjects: 0
Study: 31760536

Group type: EXPERIMENTAL
Intervention: Home-based HIV self-testing with video-chat counseling
Number of subjects: 202

Group type: COMPARATOR
Intervention: Home-based HIV self-testing
Number of subjects: 202
Study: 30970430

Group type: EXPERIMENTAL
Intervention: Prognostic nomograms for disease-free survival (DFS)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Prognostic nomograms for overall survival (OS)
Number of subjects: 385
Study: 28977796

Group type: EXPERIMENTAL
Intervention: Stannous/Sodium Fluoride (SnF/NaF, 1,450 ppm F-, 1,090 ppm Sn2+)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sodium Fluoride/Stannous Chloride/Chitosan (NaF/Sn/Ch, 1,450 ppm F-, 3,500 ppm Sn2+, 0.5% Ch)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sodium Fluoride (NaF, 1,450 ppm)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (0 ppm F)
Number of subjects: 20
Study: 26559131

Group type: EXPERIMENTAL
Intervention: Active for Life Year 5 (AFLY5) intervention
Number of subjects: 95
Study: 23140115

Group type: EXPERIMENTAL
Intervention: Aromatherapy (mixture of essential oils: peppermint, basil, and helichrysum)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (rose water)
Number of subjects: 14
Study: 21270184

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (home video visits with a diabetes educator and glucose uploads every 4-6 weeks)
Number of subjects: 1665

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1665
Study: 19627887

Group type: COMPARATOR
Intervention: Standard back pain education (group 1)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Conventional physical therapy (group 2)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Functional movement training (group 3)
Number of subjects: 61
Study: 16423355

Group type: EXPERIMENTAL
Intervention: Level one responders
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Level two responders
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 3
Study: 15531171

Group type: EXPERIMENTAL
Intervention: Traumatic Brain Injury (TBI) group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 20
Study: 11483268

Group type: EXPERIMENTAL
Intervention: Vaqta
Number of subjects: 127

Group type: COMPARATOR
Intervention: Avaxim
Number of subjects: 127
Study: 9256119

Group type: EXPERIMENTAL
Intervention: Idarubicin 12 mg/m2/d for 3 days in combination with fludarabine and cytarabine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Fludarabine and cytarabine (loading dose of 10.5 mg/m2 followed by continuous infusion of 30.5 mg/m2/24 hours for 48 hours, followed by cytarabine loading dose 390 mg/m2, then continuous infusion 101 mg/m2/h for 72 hours)
Number of subjects: 11
Study: 8491664

Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Number of subjects: 0
Study: 3321925

Group type: EXPERIMENTAL
Intervention: 0.75 micrograms alpha-calcidol (1 alpha(OH)D3) daily
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 31228414

Group type: EXPERIMENTAL
Intervention: OB Nest (reduced-visit prenatal care model with remote monitoring)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care (12 prescheduled prenatal clinic appointments)
Number of subjects: 300
Study: 27207825

Group type: EXPERIMENTAL
Intervention: WE-CO2
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: CO2-CO2
Number of subjects: 240

Group type: COMPARATOR
Intervention: WE-AI
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: WE
Number of subjects: 240
Study: 24618113

Group type: EXPERIMENTAL
Intervention: Total Contact Casts (TCC)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Shear-Reducing Boot (SRB)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Healing Sandals (HS)
Number of subjects: 73
Study: 23746479

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stenting (PES)
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Non-LAD PCI
Number of subjects: 1445
Study: 22145450

Group type: EXPERIMENTAL
Intervention: rhGH therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal stature children (control)
Number of subjects: 0
Study: 19770753

Group type: EXPERIMENTAL
Intervention: Low-dose phospholipid emulsion (850 mg/kg)
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: High-dose phospholipid emulsion (1350 mg/kg)
Number of subjects: 1379

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1379
Study: 16855462

Group type: EXPERIMENTAL
Intervention: acute tryptophan-depleting (aTD) drink
Number of subjects: 27

Group type: COMPARATOR
Intervention: nondepleting (nD) drink
Number of subjects: 27
Study: 12616671

Group type: EXPERIMENTAL
Intervention: Risperidone 0.5 mg twice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg once daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both drugs (Risperidone 0.5 mg twice daily and Donepezil 5 mg once daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 24
Study: 10883569

Group type: EXPERIMENTAL
Intervention: Cocaine-specific coping skills training (CST)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control treatment (meditation-relaxation)
Number of subjects: 108
Study: 9214205

Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 8256189

Group type: EXPERIMENTAL
Intervention: Cefepime (2 grams every 12 hours)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Gentamicin (1.5 mg/kg every 8 hours) plus Mezlocillin (3 grams every 4 hours)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 120

Group type: COMPARATOR
Intervention: Gentamicin and Mezlocillin
Number of subjects: 120
Study: 3543180

Group type: EXPERIMENTAL
Intervention: Oral decongestant-antihistamine combination and mucolytic preparation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 30815761

Group type: EXPERIMENTAL
Intervention: 1 month of online self-paced music training
Number of subjects: 41

Group type: COMPARATOR
Intervention: 1 month of audiobook listening
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 1 month of online self-paced music training followed by 1 month of audiobook listening
Number of subjects: 41

Group type: COMPARATOR
Intervention: 1 month of audiobook listening followed by 1 month of music training
Number of subjects: 41
Study: 27941535

Group type: EXPERIMENTAL
Intervention: EC-MPS
Number of subjects: 36
Study: 25524227

Group type: EXPERIMENTAL
Intervention: Cage group 1
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Cage group 2
Number of subjects: 88
Study: 24701663

Group type: EXPERIMENTAL
Intervention: First drop of cerebrospinal fluid
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Third drop of cerebrospinal fluid
Number of subjects: 39

Group type: COMPARATOR
Intervention: Spinal needle
Number of subjects: 39
Study: 21147414

Group type: EXPERIMENTAL
Intervention: Traditional Thai massage (TTM)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (rest on bed)
Number of subjects: 36
Study: 19917842

Group type: EXPERIMENTAL
Intervention: Telephone caseworker (TCW) model
Number of subjects: 356

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Oncologist/general practitioner (O/GP) model
Number of subjects: 356
Study: 17106543

Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy (LM)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Open myomectomy (AM)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 15285974

Group type: EXPERIMENTAL
Intervention: Phased 'step-down' specialist psychosocial program (including a briefer residential stay and an outpatient component)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Long-term psychoanalytically oriented residential specialist program
Number of subjects: 143

Group type: COMPARATOR
Intervention: General community psychiatric model
Number of subjects: 143
Study: 11853215

Group type: EXPERIMENTAL
Intervention: Marina (artificial mineral water containing K+ and Mg2+ ions), 4 x 200 ml daily for 7 days
Number of subjects: 0
Study: 9757888

Group type: EXPERIMENTAL
Intervention: Unextracted urine measurement of FSH
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Storage conditions for urine
Number of subjects: 40
Study: 7915076

Group type: EXPERIMENTAL
Intervention: Succinylcholine (1 mg.kg‐1) followed by vecuronium (0.15 mg.kg‐1)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no succinylcholine, vecuronium 0.15 mg.kg‐1)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups (supplemental vecuronium 0.04 mg.kg‐1)
Number of subjects: 54
Study: 2656959

Group type: EXPERIMENTAL
Intervention: Acetaminophen, 10 mg/kg/dose, given at 8 AM, 12 PM, 4 PM, and 8 PM for 4 days.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 5015033

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hyoscine 0.4 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hyoscine 0.6 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pethidine 50 mg
Number of subjects: 100
Study: 29036433

Group type: EXPERIMENTAL
Intervention: Patients with CAC
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Patients with LVH
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Patients with LVH and CAC
Number of subjects: 252

Group type: COMPARATOR
Intervention: Patients without CAC and without LVH
Number of subjects: 252
Study: 27220976

Group type: EXPERIMENTAL
Intervention: Tailored matched-message condition (N=356)
Number of subjects: 2140

Group type: EXPERIMENTAL
Intervention: Non-tailored unmatched-message condition (N=355)
Number of subjects: 2140

Group type: COMPARATOR
Intervention: Typical message with professional design (Control, N=717)
Number of subjects: 2140

Group type: COMPARATOR
Intervention: Typical message without professional design (Control, N=712)
Number of subjects: 2140
Study: 25015838

Group type: EXPERIMENTAL
Intervention: Primary care-based long-term program including discharge management, training of general practitioners and patients, and telephone monitoring.
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Primary care-based long-term program
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 290
Study: 24421235

Group type: EXPERIMENTAL
Intervention: Sequential enteral nutrition (Group A)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional enteral nutrition (Group B)
Number of subjects: 49
Study: 20589596

Group type: EXPERIMENTAL
Intervention: Pharmacotherapeutic management of aggression
Number of subjects: 0
Study: 17964657

Group type: EXPERIMENTAL
Intervention: AcrySof intraocular lenses (IOLs)
Number of subjects: 1202
Study: 16361856

Group type: EXPERIMENTAL
Intervention: High-flux membranes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Medium-flux membranes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-flux membranes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Plasma carbonyl residues
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Advanced oxidation protein products (AOPPs)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Correlation between plasma-induced proapoptotic activity and plasma carbonyl levels
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Correlation between plasma-induced proapoptotic activity and AOPP levels
Number of subjects: 10
Study: 14521681

Group type: EXPERIMENTAL
Intervention: Follow-up nursing interventions for patients with diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rheumatology nurse specialist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multidisciplinary team in day care or inpatient settings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple, long-term follow-up visits by nurses
Number of subjects: 0
Study: 11049945

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 10
Study: 8913408

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Acarbose in combination with sulfonylureas
Number of subjects: 25
Study: 1562921

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ringer's lactate (RL)
Number of subjects: 28
Study: 4083302

Group type: EXPERIMENTAL
Intervention: 7 P.M. dosing with 800 mg of Uniphyl
Number of subjects: 16
Study: 30449692

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 29557250

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40 IU)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (saline-soaked gel foam)
Number of subjects: 38
Study: 28300804

Group type: EXPERIMENTAL
Intervention: Adaptol
Number of subjects: 62

Group type: COMPARATOR
Intervention: Noophen
Number of subjects: 62
Study: 25357174

Group type: EXPERIMENTAL
Intervention: 1,320-nm Nd:YAG laser treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham treatment of cryogen cooling only
Number of subjects: 10
Study: 23923184

Group type: EXPERIMENTAL
Intervention: Antenatal exercises
Number of subjects: 0
Study: 20836133

Group type: EXPERIMENTAL
Intervention: Postural drainage with percussion (PD)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Autogenic drainage (AD)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Both AD and PD
Number of subjects: 36
Study: 18411009

Group type: EXPERIMENTAL
Intervention: Daily Sleep Interference Scale (DSIS)
Number of subjects: 2158
Study: 15737445

Group type: EXPERIMENTAL
Intervention: Spastic cerebral palsy group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 20
Study: 12969711

Group type: EXPERIMENTAL
Intervention: N,O-carboxymethylchitosan (NOCC) - 200 mL of 1% NOCC gel followed by 100 mL of 2% NOCC solution
Number of subjects: 34

Group type: COMPARATOR
Intervention: Ringer's lactate
Number of subjects: 34
Study: 11029555

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid injections
Number of subjects: 336
Study: 8730521

Group type: EXPERIMENTAL
Intervention: Positively worded statements
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Negatively worded statements
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Paired statements
Number of subjects: 116
Study: 1378783

Group type: EXPERIMENTAL
Intervention: Slow release gallopamil 100mg twice daily
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13